Just four months into trading from its Nottingham UK base, XenoGesis Limited has exceeded its initial sales targets by more than 300%. The BioCity Nottingham contract research organisation began trading in early November and was providing laboratory-based drug analysis services to major global pharmaceutical clients from day one.
Started by former Associate Principal Scientist in drug metabolism & pharmacokinetics (DMPK) at AstraZeneca Dr Richard Weaver, the company has also attracted £135,000 investment to enable the purchase of laboratory and IT equipment and to support its marketing activities. The company already employs two senior scientists, Dr Manfred Ismair and Dawn Parkins who worked with Dr Weaver in AstraZeneca, and is set to take on an Associate research scientist in April.
The encouraging sales achievements are the result of several international visits as well as Dr Weaver’s considerable reputation in the pharmaceutical sector. XenoGesis specialises in pre-clinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation. Their laboratory tests demonstrate how the human body might affect the way a drug behaves. Backing this up with advice on how to modify the chemical structure of a compound to make it more ‘drug-like’ makes the XenoGesis service attractive to global drug companies.
Keep Reading...
Monday 5th March 2012
Mobius Life Sciences Fund has announced an investment in XenoGesis Limited, the contract research organisation (CRO) which provides laboratory-based services to pharmaceutical clients engaged in drug discovery. Mobius’ financing is part of a £135,000 investment round in the fast-growing start-up company, which includes loan funding from Nottingham City Council. The funds will be used for working capital and investment in both laboratory and office IT infrastructure. Mobius investment also comes with industry expertise in company growth.
Based in BioCity Nottingham, XenoGesis specialises in pre-clinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation. Their laboratory tests demonstrate how the human body might affect the way a drug behaves. Backing this up with advice on how to modify the chemical structure of a compound to make it more ‘drug-like’ makes the XenoGesis service attractive to global drug companies. Just four months since launch, the company has already signed-up several international clients.
Keep Reading...
Findings of the 2011 UK Life Science Start up report ‘Transition’
Press interviews with Dr Glenn Crocker from 12:00 on Thursday 1st December at QE11 Conference Centre or by prior arrangement
Commercial laboratories across the UK are becoming part of a silent, but significant revolution in the way the life science industry operates. The impact, according to the UK Life Science Start up report published today, is already affecting the way the industry is structured, how and where new start ups come from, and the source and nature of early-stage finance.
The overall picture is of an industry in transition, with a changing base of businesses and an evolving funding ecosystem.
The UK Life Science Start-up report 2011 is the second comprehensive study of early stage life science firms. This new study considers companies formed in the period 2006-2010 and allows a comparison with the findings of the 2010 report which looked at the period 2005-2009. The findings provide an insight into where the new start-ups are coming from, what fields they specialise in and the investment they are raising.
Author of the report and CEO of BioCity, Dr Glenn Crocker will draw from these findings, and call for action, in his presentation to the gathering of life science industry experts at the 2011 Genesis conference in London on 1st December.
Keep Reading...
Which thinker has emerged over the last two years with the potential to change the world of theory and practice? The answer to this question posed by Thinkers50 is Lucy P. Marcus, the Anglo-American board chair and non-executive director who challenges conventional wisdom both inside and out of the boardroom.
The Thinkers50 is the definitive global ranking of management thinkers, published every two years. Marcus is the recipient of the Future Thinker Award, one of eight new awards that coincide with the ranking and recognize leaders in the fields of: innovation; strategy; globalization; and leadership; as well as the best emerging thinker; the most significant breakthrough idea; and the most important book of the last two years.
THINKERS 50 2011: THE FUTURE THINKER AWARD SHORTLIST
Keep Reading...